Head-To-Head Survey: Scinai Immunotherapeutics (NASDAQ:SCNI) & Humacyte (NASDAQ:HUMA)

Humacyte (NASDAQ:HUMA) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk.

Profitability

This table compares Humacyte and Scinai Immunotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Humacyte	-3,955.05%	-612.88%	-80.03%
Scinai Immunotherapeutics	N/A	N/A	N/A

Insider and Institutional Ownership

44.7% of Humacyte shares are held by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are held by institutional investors. 3.1% of Humacyte shares are held by company insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Humacyte has a beta of 2.64, suggesting that its share price is 164% more volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.27, suggesting that its share price is 127% more volatile than the S&P 500.

Valuation and Earnings

This table compares Humacyte and Scinai Immunotherapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04 million	76.04	-$40.83 million	($0.44)	-1.27
Scinai Immunotherapeutics	$1.31 million	0.41	-$8.31 million	$8.66	0.05

Scinai Immunotherapeutics has lower revenue, but higher earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Humacyte and Scinai Immunotherapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1	1	6	0	2.62
Scinai Immunotherapeutics	1	0	0	0	1.00

Humacyte currently has a consensus price target of $4.48, suggesting a potential upside of 702.52%. Given Humacyte’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Humacyte is more favorable than Scinai Immunotherapeutics.

Summary

Scinai Immunotherapeutics beats Humacyte on 8 of the 14 factors compared between the two stocks.

About Humacyte

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for vascular repair and other medical applications. Its technology uses human vascular cells to create vessels that are processed to remove the cells, leaving an acellular structure designed for implantation. The company’s lead product, Symvess, is an acellular tissue-engineered vessel for treating extremity arterial injuries in adults when a patient’s own vein cannot be used for surgical revascularization. The U.S. Food and Drug Administration approved Symvess in December 2024.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) is an Israel-based clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for autoimmune and inflammatory diseases. The company’s research is centered on treatments intended to modulate disease-related immune responses while potentially limiting systemic exposure and associated side effects. Scinai’s technology platform is based on NanoAb antibody fragments, which are designed to bind specific biological targets and may be suitable for local administration.